About ABBV-744 as a potential therapeutic option for aggressive cancers
The current work examined the potential of making use of ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant as well as palbociclib. ARV-825 was effective in both p53 wild-variety (WT) breast tumor cells As well as in cells missing functional p53 either on your own or in combination with tamoxifen, when the effectiveness o